Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.39 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.39 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7071897 | 0.85 | TPSAB1 (0.39) | TPSAB1TPSD1TPSG1MAPTSMN1; SMN2 | |
| SCHEMBL7075013 | 0.81 | TPSAB1 (0.38) | TPSAB1TPSD1TPSG1HPGD | |
| SCHEMBL7069767 | 0.79 | TPSAB1 (0.37) | TPSAB1TPSD1TPSG1GAAMAPT | |
| SCHEMBL7068114 | 0.79 | TPSAB1 (0.38) | TPSAB1TPSD1TPSG1POLBHPGD | |
| SCHEMBL7070029 | 0.78 | TPSAB1 (0.38) | TPSAB1TPSD1TPSG1MAPTALDH1A1 | |
| SCHEMBL7847240 | 0.78 | POLB (0.40) | TPSAB1TPSD1TPSG1GAATHRB | |
| SCHEMBL7069757 | 0.77 | MAPT (0.52) | TPSAB1TPSD1TPSG1GAATHRB | |
| SCHEMBL7075009 | 0.77 | TPSAB1 (0.38) | TPSAB1TPSD1TPSG1HPGD | |
| SCHEMBL7072410 | 0.75 | MAPT (0.43) | TPSAB1TPSD1TPSG1GAAMAPT | |
| SCHEMBL7072213 | 0.75 | TPSAB1 (0.39) | TPSAB1TPSD1TPSG1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | TPSAB1 5/4885TPSD1 6/4885TPSG1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.